Kornimate/medical-research-clean huggingface dataset:
comparing different diameter furss with similar resds for the treatment of upper urinary tract stones

Conditions: Ureter Injury; Urolithiasis; Lower Urinary Tract; Efficacy, Self

Summary: comparing the efficiency, effectiveness, and safety of furs lithotripsy with similar resds in the treatment of upper urinary tract stones.

comparing the efficiency, effectiveness, and safety of furs lithotripsy with similar resds in the treatment of upper urinary tract stones.

Eligibility criteria:
inclusion criteria: - 1.patients with kidney stones or upper ureteral stones with a cumulative diameter of less than 3 cm are selected for ureteral soft lens holmium laser lithotripsy. 2.age 18 to 80 years old, gender unlimited. 3.the subjects have no mental illness or language dysfunction, can understand the situation of the study and can sign informed consent. exclusion criteria: * 1.patients with a history of ureteral stenosis or who have undergone open or laparoscopic ureteral or renal lithotomy. 2.patients with fever one week before surgery 3.pregnant women and menstruating patients. 4.patients with combined systemic disease or inability to tolerate anesthesia. 5.patients undergoing simultaneous surgery for bilateral upper urinary tract stones. 6.patients with ureteral stent indwelling before surgery. 7.in patients with severe hydronephrosis, the separation of the renal collecting system is greater than 4 cm. 8.patients with renal anatomic malformations such as polycystic kidney, horseshoe kidney, and ectopic kidney.

Keywords: urolithiasis ratio of endoscope-sheath diameter flexible ureteroscope
covid-19 and mental health in eure

Conditions: COVID-19 Pandemic; Psychiatric Disorder

Summary: research hypothesis: living conditions during covid-19, and lockdowns and curfews impact the psychological state of patients (assessed by the degree of depression, positive and negative thoughts, insomnia, state of post-traumatic stress).

from the early stages of the covid-19 pandemic, concerns were raised about its effect on mental health and on patients with mental illness. several surveys and cross-sectional assessments, in italy, england, ecuador and china in 2020, have suggested that patients with covid-19 have symptoms of anxiety (including stress disorder traumatic, depression and insomnia. in france, a survey by "santé publique france" on the impact of covid-19 on mental health carried out in november 2020, revealed a 20% rate of depressive symptoms in the general population. the objective of this study is to assess the level of psychological distress and the prevalence of psychiatric disorders related to covid-19 as part of the follow-up of psychiatric patients in the department of eure since march 2020, which has coincided with the onset of the health crisis, including consecutive lockdowns and curfews.

Eligibility criteria:
inclusion criteria: * at least 18 years old * coming for a psychiatric consultation or hospitalization at the new hospital of navarre or in the extra-hospital centers of the department of eure * patient who has received the information note and who does not refuse to participate in the study exclusion criteria: * patient not understanding french * patient followed in psychiatry for a major cognitive disorder * patient under legal protection measure (guardianship, curatorship, safeguard of justice, future protection mandate or family authorization)

Keywords: covid-19 psychiatry
evaluating the pharmacokinetics and pharmacodynamics of romiplostim in patients with immune thrombocytopenia (itp)

Conditions: Immune Thrombocytopenia (ITP)

Summary: the objective of evaluating the pharmacokinetics and pharmacodynamics of romiplostim in patients with immune thrombocytopenia.


Eligibility criteria:
inclusion criteria: * diagnosed with immune thrombocytopenia (itp) for at least 6 months prior to signing the informed consent form (icf). * subject is ≥ 18 years old and ≤ 70 years old while signing the icf. * patients who have no response or relapsed after splenectomy. or patients who have not been splenectomised and have completed at least 1 prior treatment for itp. excluded having previously received recombinant human thrombopoietin (rhutpo) or any other thrombopoietin receptor agonist. * the mean of 3 scheduled platelet counts taken during the screening period must be: \ 35×10\^9/l. exclusion criteria: * any known history of bone marrow stem cell disorder. any abnormal bone marrow findings other than typical of itp. * any active malignancy. if prior history of cancer other than basal cell carcinoma or cervical carcinoma in situ, no treatment or active disease within 5 years prior to signing the icf. * had received eltrombopag, recombinant human thrombopoietin (rhutpo) or other myeloproliferative leukemia (mpl) stimulation product. * received hematopoietic growth factors (e.g., granulocyte colony-stimulating factor, macrophage colony-stimulating factor, erythropoietin, interleukin-11) for any reason within 4 weeks prior to signing the icf. * received any anti-malignancy agents (e.g., cyclophosphamide, 6-mercaptopurine, vincristine, vinblastine, interferon-alfa) for any reason within 8 weeks prior to signing the icf. * received any monoclonal antibody drugs (e.g., rituximab) for any reason within 14 weeks prior to signing the icf. * less than 4 weeks since end of any clinical trials about therapeutic drug or device for any indication prior to signing the icf. * pregnant or breast feeding. * in the opinions of the principal investigator or investigators, the patients are not suitable for participation in this trial.
a trial assessing feasibility of allostatic load biomarkers and cvd risk among black breast cancer survivors

Conditions: Breast Cancer

Summary: this study's overall objective is to test the effects of a culturally tailored gratitude, exercise, and mindfulness/emotional freedom techniques (gem) psychosocial intervention on allostatic load and atherosclerotic cardiovascular disease risk in black women breast cancer survivors. allostatic load refers to the cumulative physiological burden of chronic stress, which is a major contributor to cvd risk, impaired immune function, and worse cancer outcomes. atherosclerotic cardiovascular disease risk encompasses factors such as blood pressure, cholesterol, and glucose control that predict long-term cardiovascular health. among survivors of breast cancer in the u.s., black women have the highest rates of mortality from breast cancer, cardiometabolic disease, and all causes. these disparities are likely due to complex interactions between socioeconomic, psychosocial, and biological risk factors. a higher prevalence of cardiometabolic risk factors among black women breast cancer survivors is one critical disparity associated with poorer breast cancer outcomes and increased cardiometabolic risk, including that driven by cardiotoxicity from breast cancer treatment. engagement in physical activity, which reduces cardiometabolic risk, is associated with significant reductions in all-cause and cancer mortality in breast cancer survivors. however, black breast cancer survivors report lower levels of physical activity compared to their white counterparts, and most interventions targeting this behavior have not effectively engaged black women. interventions that effectively increase physical activity in black women breast cancer survivors hold promise as a means for reducing these persistent disparities in survival outcomes.


Eligibility criteria:
inclusion criteria: * participants must identify as black women who have survived breast cancer * participants must have completed primary cancer treatment (surgery, chemotherapy, and/or radiation) at least 6 months prior to enrollment * adults ≥ 18 years old * capable of completing study requirements * informed consent obtained from the participant and documentation of participant agreement to comply with all study-related processes exclusion criteria: * females who are pregnant or breastfeeding * prisoners or subjects who are involuntarily incarcerated, or subjects who are compulsorily detained for treatment of either a psychiatric or physical illness. * impaired cognition (i.e., inability to follow and respond appropriately during screening). * participants currently enrolled in other lifestyle, exercise, or psychosocial interventions will be excluded.

Keywords: black breast cancer survivors allostatic load atherosclerotic cardiovascular disease
reflux-induced oxidative stress in barrett's esophagus: response, repair, and epithelial-mesenchymal-transition

Conditions: Barrett's Esophagus; Gastroesophageal Reflux Disease

Summary: the purpose of this study is to elucidate mechanisms whereby oxidative stress induced by acute reflux esophagitis: 1) activates p38 to regulate proteins that control the g1/s cell cycle checkpoint, and 2) activates hifs (hypoxia inducible factors) to cause autocrine vegf (vascular endothelial growth factor) signaling that triggers the emt (epithelial-mesenchymal-transition) program in barrett's esophagus.

gastroesophageal reflux disease (gerd) and its complication, barrett's esophagus (be), are risk factors for esophageal adenocarcinoma. in be, gerd causes inflammation with oxidative dna damage and genomic instability that contributes to carcinogenesis. in be, one response to oxidative stress is p38 pathway activation, which might protect against cancer development by initiating g1 arrest and enabling repair of dna damage. inflammation and oxidative stress also might induce epithelial-mesenchymal transition (emt), the process in which epithelial cells acquire mesenchymal characteristics including the ability to migrate. this study will elucidate mechanisms whereby the oxidative stress of acute reflux esophagitis in be activates p38 to regulate proteins controlling the g1/s cell cycle checkpoint, and activates hifs to cause autocrine vascular endothelial growth factor (vegf) signaling that triggers the emt program.

Eligibility criteria:
inclusion criteria: * u.s. veteran * barrett's esophagus exclusion criteria: * inability to provide informed consent * pregnancy or breastfeeding * esophageal varices * warfarin use * coagulopathy that precludes safe biopsy of the esophagus * comorbidity that precludes safe participation in the study

Keywords: barrett's esophagus gastroesophageal reflux disease
ecco2r - mechanical power study

Conditions: ARDS, Human; Extracorporeal CO2 Removal; Mechanical Power

Summary: although mechanical ventilation remains the cornerstone of ards treatment, several experimental and clinical studies have undoubtedly demonstrated that it can contribute to high mortality through the developing of ventilator induced lung injury even in patients with plateau pressure \<30 cmh2o. since now there are no studies exploring the application of low flow extracorporeal co2 removal and ultraprotective ventilation to reduce mechanical power, a composite index of vili, independently from the value of plateau pressure or the severity of hypercapnia.


Eligibility criteria:
inclusion criteria: ards patients undergoing mechanical ventilation with: * pao2/fio2 \ 0.5 * plateau pressure of 28 cmh2o or higher with tidal volume of 6 ml/kg of ideal body weight * mechanical power of 18 j/min or higher. exclusion criteria: * \<18 years of age * pregnancy * obesity with bmi\> 30 * platelets \<30 g/l * decompensated heart failure or acute coronary syndrome * acute brain injury * contraindication for systemic anticoagulation (for example, gastrointestinal bleeding, recent cerebrovascular accident, or chronic bleeding disorder, recent major surgery) * patient moribund, decision to limit therapeutic interventions * catheter access to femoral vein or jugular vein impossible * pneumothorax.
efficacy and safety of venetoclax combined with dexamethasone and etoposide in hlh

Conditions: Hemophagocytic Lymphohistiocytosis

Summary: this study aimed to investigate the efficacy and safety of venetoclax combined with dexamethasone and etoposide as a salvage therapy for hemophagocytic lymphohistiocytosis.

hemophagocytic lymphohistiocytosis (hlh) is a rare and aggressive disease with high mortality and poor prognosis. the hlh-94 and hlh-04 regimens are most commonly used, but approximately 30% of the patients remain unresponsive. currently, there is no unified evidence-based salvage treatment. there is no unified salvage regimen. this study plans to enroll 20 patients with refractory and recurrent hemophagocytic lymphohistiocytosis. subjects will receive venetoclax combined with dexamethasone and etoposide for 8 weeks.the safety was evaluated once a week, and the efficacy was evaluated once every 2 weeks. overall response rate will be evaluated at 8 weeks. patients were followed up every 3 months thereafter.

Eligibility criteria:
inclusion criteria: * age ≥18 years old, expected survival time more than 3 months; * met hlh-2004 diagnostic criteria； * ecog score 0-2； * ecg qtcf interval: male ≤450ms, female ≤470ms; * ast and alt ≤3.0 uln, tb ≤1.5×uln；serum creatinine≤1.5×uln，or crcl ≥ 50ml/min；inr、aptt、pt ≤1.5×uln； * without pregnancy or lactation, and agree to contraception during and for at least 6 months after the study； * signed informed consent. exclusion criteria: * patients with malignancies unrelated to hlh, except for fully recovered non-melanoma skin cancer and carcinoma in situ; * patients participated in other clinical trials within 4 weeks； * previously treated with bcl-2 inhibitors； * unable to take oral medication； * history of substance abuse or patients with mental illness； * severe infection； * cardiovascular disease，nyha ii-iv； * allergic to venetoclax or etoposide.

Keywords: hemophagocytic lymphohistiocytosis venetoclax
self-management interventions for chronic pain relief with cancer survivors

Conditions: Chronic Pain

Summary: cancer survivors who suffer from chronic pain would benefit from a low-cost, self-management intervention they can use at home. this study will evaluate the efficacy of a recorded hypnosis intervention in reducing chronic pain among cancer survivors and will explore its biological and psychological mechanisms.

the purpose of this randomized controlled trial is to evaluate if a 4-week recorded hypnosis intervention (rhi) works for reducing chronic pain in 100 adult cancer survivors who have completed active treatment. the rhi will be compared to an attention control condition (relaxation recording). qeeg measurement will be obtained while listening to the rhi at weeks 0, 2, and 4 to explore if brain states are related to hypnotic analgesia during the 4-week study period in 20 study participants. the study has the following specific aims: aim 1: does the rhi work? evaluate the efficacy of rhi in reducing self-reported pain intensity (primary outcome), pain interference, anxiety, depression, fatigue and sleep disturbance (secondary outcomes) at 4 weeks compared to the attention control condition (relaxation recording). hypothesis: rhi will significantly reduce pain intensity, pain interference, anxiety, depression, fatigue, and sleep disturbance at 4 weeks. aim 2: for whom does the rhi work? examine if psychological factors (hypnotic suggestibility, mental absorption, treatment outcome expectancy, fear of cancer recurrence, resilience, self-efficacy) influence the relationship between rhi and pain intensity at weeks 0, 2, and 4. aim 3: how does the rhi work? a. compare brain activity as measured by electroencephalogram (eeg) in cancer survivors with chronic pain (n=30) receiving the rhi relative to the attention control condition (relaxation recording) at weeks 0, 2, and 4. b. explore the effects of brain activity on pain intensity at weeks 0, 2, and 4. in addition, structured interviews will be conducted with participants to understand facilitators and barriers associated with undergoing eeg at three time points and perceptions on how the intervention works to reduce pain.

Eligibility criteria:
inclusion criteria: * self-reporting moderate or higher pain on average during the last week (\> 3 on a 0-10 pain intensity numeric scale) * self-reporting experiencing pain at least half of the days in the past 4 weeks * self-reporting chronic pain related to cancer or its treatment * completed active cancer treatment other than maintenance therapy * being \> 18 years of age * functional fluency in english * mentally and physically able to participate and complete surveys exclusion criteria: • has a psychiatric condition or symptoms (i.e., diagnosis of paranoid schizophrenia or active paranoid delusional thoughts, as determined via a telephone or in-person screening assessment) that would interfere with study participation. exclusion criteria for optional eeg measurement: * a history of seizure condition within the last year * a significant brain injury or skull defect * a history of brain cancer.
the effect of mobile augmented reality application on nursing students' knowledge skills and motivation

Conditions: Education; Nursing

Summary: the aim of this study was to examine the effects of a mobile augmented reality application on nursing students' knowledge, skills, and motivation regarding pressure injuries.

the research is a randomized controlled, quasi-experimental study. the population of the study consisted of 130 first-year students enrolled at gülhane faculty of nursing, university of health sciences. in the study, a mobile augmented reality application was used for the training of students in the intervention group regarding pressure injury prevention. the training of the control group students continued with traditional education methods. the data collection process of the study was carried out in two stages: preparation and implementation. prior to the commencement of the study, ethical committee approval and institutional permissions were obtained. in the analysis of the data, descriptive statistical methods such as number, percentage, min-max values, median, mean, and standard deviation were used, along with independent t-test, dependent t-test, and chi-square analysis.

Eligibility criteria:
inclusion criteria: * volunteering to participate in the study. * taking the fundamentals of nursing course for the first time. exclusion criteria: * using a language other than turkish as a native language. * graduating from a vocational health high school. * being enrolled in the nursing faculty through vertical transfer. * working as a nurse or healthcare staff in a hospital or any healthcare institution. * being excluded from the control and experimental groups during randomization.

Keywords: nursing pressure injury augmented reality
the improving attendance to cardiac rehabilitation trial

Conditions: Myocardial Infarction; Heart Failure; Heart Valve Diseases; Cardiac Event; Angina Pectoris; Coronary Artery Disease

Summary: the benefits of cardiac rehabilitation are well known. however, despite center based cardiac rehabilitation (cbcr) representing guideline-based care for patients with cardiovascular disease, most patients do not complete the maximum number of sessions allowed by third party insurance payers. as such, many patients may not be receiving the full clinical benefit ascribed to cr. this study will assess the efficacy of an innovative approach to cr delivery on attendance by combining both center-based and remote- or home-based cr sessions. the intervention group combines center-based cr and remote-/home-based cr and is tailored to the individual needs of each patient, accomplished with the assistance of an easy-to-access telecommunications methodology (telemedicine)


Eligibility criteria:
inclusion criteria: 1. has agreed to participate in cr and has experienced a cardiac event (myocardial infraction, coronary revascularization, heart valve surgery, or cardiac transplant in the past 6 months; diagnosed with chronic, stable aha/acc stage b or c heart failure or canadian class 0-2 stable angina pectoris) 2. lives in or plans to remain in the greater detroit, mi area for the next year 3. age 18-85 years of age 4. agrees to attend at least one cbcr session 5. agrees to scheduling at least 2, up to 3, cr sessions (either cbcr or hycr)/wk 6. has demonstrated to research staff their ability to access and connect to the internet via smart phone or tablet and already has access to satisfactory home- or community-based exercise equipment exclusion criteria: 1. received a left ventricular assist device, receiving continuous inotropic support (e.g., milrinone), or undergoing hemodialysis 2. angina at rest or with a low functional capacity (\< 2 mets) 3. advanced cancer, advanced risk for falling, limiting cognitive impairment, or other advanced disorder that limits participation in cr 1. advanced risk for falling will be assessed by 5x sit-to-stand test, with a cut-off score of \>15 seconds 2. cognitive assessment will be completed using the mini-cog instrument, with a cut-off score \< 3 used to exclude potential subjects. 4. severe arrhythmia unless adequately treated (e.g., implantable cardiac defibrillator) 5. pregnant or plan to become pregnant in the next year. 6. major cardiovascular procedure or hospitalization planned in the next 6 months 7. less than 12 month life expectancy 8. participation in another clinical trial that interferes with iattend participation, follow-up, data collection, exercise capacity or quality of life.
topo-guided lasik and photorefractive keratectomy vs wavefront lasik and photorefractive keratectomy

Conditions: Surgery; Myopia

Summary: this study evaluates the difference in results between eyes that have been treated wavefront optimized laser vision correction (either lasik or photorefractive keratectomy) compared to eyes treated with topography-guided laser vision correction (either lasik or photorefractive keratectomy). each participant will receive wavefront optimized correction in one eye and topography-guided correction in the other.

participants will have an in depth discussion with our refractive surgery coordinator regarding refractive surgery. patients will choose lasik or photorefractive keratectomy surgery based on our standard pre-operative discussion that is provided to all patients. as is standard for laser refractive candidates, the advantages and disadvantages of lasik and photorefractive keratectomy compared to the other refractive surgical options will be discussed. following patient selection of their preferred type of refractive procedure they will be randomized as discussed below, and only patients who elect for lasik or photorefractive keratectomy will be included in our study. prior to surgery, one eye from each patient will be randomly assigned to receive either wavefront optimized or topography guided treatment. each patient in the study will have a fellow eye enrolled in the other treatment group. patients will either receive lasik treatment or photorefractive keratectomy treatment in both eyes but the eyes will be randomized to topography guided or wavefront optimized forms of treatment.

Eligibility criteria:
inclusion criteria: * all subjects who are deemed suitable candidates for laser refractive surgery after routine refractive surgery screening will be considered eligible for participation in this study. subjects must be at least 21 years of age and not pregnant or nursing (due to fluctuations in visual parameters during pregnancy) exclusion criteria: * any patient who is not a suitable candidate for lasik or prk will not be included.

Keywords: photorefractive keratectomy laser-assisted in situ keratomileusis